Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Upstream Bio

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From Upstream Bio
Via GlobeNewswire
Tickers UPB
Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team
From Upstream Bio
Via Business Wire
Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients
From Upstream Bio
Via Business Wire
Upstream Bio Announces Dosing of First Patients in a Phase 2 Clinical Trial of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
From Upstream Bio
Via Business Wire
Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2
From Upstream Bio
Via Business Wire
Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases
From Upstream Bio
Via Business Wire
Upstream Bio Presents New Phase 1 Clinical Data on UPB-101 at the American Thoracic Society (ATS) International Conference
From Upstream Bio
Via Business Wire
Upstream Bio to Present New Clinical Data from Phase 1 Study of UPB-101 at the American Thoracic Society (ATS) International Conference
From Upstream Bio
Via Business Wire
Upstream Bio Announces the Appointment of Marcella Ruddy, M.D., to the Board of Directors
From Upstream Bio
Via Business Wire
Upstream Bio Announces Clinical Advisory and Leadership Appointments
From Upstream Bio
Via Business Wire
Upstream Bio Announces Dosing of First Patient in a Phase 1b Clinical Trial of UPB-101 in Asthma
From Upstream Bio
Via Business Wire
Upstream Bio Launches with $200M Series A Financing to Advance Novel Therapeutics for Allergic and Inflammatory Diseases
From Upstream Bio
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.